Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30196% above fair value
$11.62+0.72 (+6.61%)
Close on Nov 13, 2026Market cap $407.48MP/E 387.3Yield –
Fennec Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Fennec Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was 5.6%. For fiscal 2025 it was -14.1%, against 5.4% the year before. The highest annual figure on record is 5.4% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -14.1% | −19.5 |
| FY2024 | Dec 31, 2024 | 5.4% | +65.5 |
| FY2023 | Dec 31, 2023 | -60.1% | +1411.5 |
| FY2022 | Dec 31, 2022 | -1471.6% | +7470.9 |
| FY2020 | Dec 31, 2020 | -8942.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 23.7% | +25.3 |
| Q2 FY2026 | Jun 30, 2026 | 9.7% | +38.0 |
| Q1 FY2026 | Mar 31, 2026 | -0.8% | +8.4 |
| Q4 FY2025 | Dec 31, 2025 | -18.5% | −6.8 |
| Q3 FY2025 | Sep 30, 2025 | -1.5% | +73.1 |
| Q2 FY2025 | Jun 30, 2025 | -28.3% | +41.1 |
| Q1 FY2025 | Mar 31, 2025 | -9.2% | −63.4 |
| Q4 FY2024 | Dec 31, 2024 | -11.8% | +6.9 |
| Q3 FY2024 | Sep 30, 2024 | -74.6% | −59.0 |
| Q2 FY2024 | Jun 30, 2024 | -69.4% | +70.9 |
| Q1 FY2024 | Mar 31, 2024 | 54.2% | +368.4 |
| Q4 FY2023 | Dec 31, 2023 | -18.7% | +1654.3 |
| Q3 FY2023 | Sep 30, 2023 | -15.6% | – |
| Q2 FY2023 | Jun 30, 2023 | -140.3% | – |
| Q1 FY2023 | Mar 31, 2023 | -314.3% | – |
| Q4 FY2020 | Dec 31, 2020 | -1673.0% | – |
See a number that looks wrong?